Rheumatoid Arthritis

Shaziya shaikh Manisha sharma Rasika natu Kriti salian Chanchal raut Shainoor sayed Rashmi jamkar

Rheumatoid arthritis
Rheumatoid arthritis

Symptoms

Symptoms

Relieved by Exercise Avoid hard work Place hot compresses

Painful joints

Painful in harmed joints

In older patient

Commercial Players

Humira (Abbot)

Enbrel (Amgen)

Remicade (J&J)

Celebrex (Pfizer)

Ornecia (Bristo-Myers)

Abbot (Humira)
Humira had 2012 global sales of $ 9.6 billion with half in Rheumatoid Arthritis In the second quarter of the year Humira sales 12%

Amgen (Enbrel)
$ 4.6 billion in RA sales 2nd best selling drug in the year Last year it was set to lose its patent in October 2012 but Amgen won new patent which will remain for 17 years

J&J (Remicade)
$ 4 billion RA sales Remicade is J&J best selling drugs EMA approved two biosimilar drug

Pfizer (Celebrex)
$ 2.1 billion RA sales Pfizer paid billion dollars to settle personal injuries

Bristo-Myers (Ornecia)

Turn Over(in Billion)

5
4 3 2 1 0 Turn Over(in Billion)

Abbot Amgen

J&J

pfizer

Myers

Patent position of RA drugs

Company Product Revenue

($ billion)
4.50

Growth

Patency number
2243459

Patent expiry
17-9-2002 to 10-2-2017 6-02-2001 to 18-3-2018 22-11-2011 to 22-11-2028 14-04-1998 to 14-04-2018 7-04-1998 to 7-04-2015 22-05-2007 to 16-06-2012

Abbott Johnson & Johnson Amgen

Humira

50%

Remicade

3.70

18%

2106299

Enbrel

3.60

12.5%

8063182

Pfizer

Celebrex

2.49

9%

5972986

Roche

Rituxan

0.75

NA

5736137

BMS

Orencia

0.44

91%

2110518

Pipeline RA drugs
Agent Tocilizumab Sponsor HoffmanLa Roche Sanofi Janssen Target Precli nical IL-6 Phase 1 Phase 2 Phase 3 Approval

Sarilumab Sirukumab Fostamatinib

IL-6 IL-6

AstraZene Syk ca Eli Lily and Co. BAFF

Tabalumab

Balimumab

GSK

BLyS

Conclusion

Reference